Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Pediatric Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1630923

This article is part of the Research TopicAddressing Cancer in Children, Adolescents, and Young Adults in Low- and Middle-Income Countries: Challenges and Opportunities for Improved OutcomesView all 6 articles

Clinical outcome of 115 patients with synchronous bilateral Wilms' tumor: largest cohort of single-center experience

Provisionally accepted
Hosam  Y. AsfourHosam Y. Asfour1*Wael  Zekri Khaled ZekriWael Zekri Khaled Zekri2M.  Hany HusseinM. Hany Hussein2Naglaa  ElKinaaiNaglaa ElKinaai3Sarah  SobhySarah Sobhy3Mahmoud  HelmiMahmoud Helmi3Azza  NasrAzza Nasr4Amal  RefaatAmal Refaat5Rana  GamalRana Gamal1Alaa  YounesAlaa Younes6Moatasem  El-AyadiMoatasem El-Ayadi2Sahar  A. KhalilSahar A. Khalil1
  • 1Department of Pediatric Oncology, Children's Cancer Hospital (Egypt), Cairo, Egypt
  • 2Department of pediatric oncology, National Cancer Institute, Egypt, Cairo, Egypt
  • 3Department of pathology, National Cancer Institute, 57357, Cairo, Egypt
  • 4Department of radiotherapy, Children's Cancer Hospital Egypt, Cairo, Egypt
  • 5Department of Radiodiagnosis, Children's Cancer Hospital Egyptg, Cairo, Egypt
  • 6Department of surgical oncology, Children's Cancer Hospital Egypt, Cairo, Egypt

The final, formatted version of the article will be published soon.

Abstract: Introduction: Bilateral Wilms' tumor (BWT) represents 5 – 8% of patients with Wilms' tumor (WT). Despite the improvement of WT survival, still patients with BWT are challenging with a high risk of relapse and renal failure. Purpose: To assess the outcome of pediatric patients with BWT treated at Children's Cancer Hospital Egypt (CCHE) 57357, and to assess the long-term nephrotoxicity among these patients. Methods: This was a retrospective study including all patients with synchronous BWT treated at CCHE 57357 from 2007 until 2020. Records of all patients were reviewed. Patients were followed up until end of December 2024. Results: In 115 eligible patients, median age was 31.5 months (range 3 month – 9 years). Male to female ratio was 1:1.67. Abdominal mass was the most common presentation (69.5%). At the end of the study, 5-year EFS and OS were 69% and 76.7%. Patients with high-risk pathology had the worst prognosis regarding EFS and OS, keeping its significance in uni-and multivariate analyses as the factor with highest hazard ratio (HR = 2.931, 95% CI 1.366 - 6.289 p 0.006). Out of 29 events related to the disease, 21 included local progression/relapse (72.5%), and 8 lung progression/relapse (27.5%). The incidence of ESRD was 6.9% (8 patients). Conclusion: Bilateral Wilms' tumor poses a significant challenge all over the world. Proper timing and type of surgery should be tailored according to each patient. Low-middle income countries face additional challenges related to supportive care for those children who usually present at a very young age with a tangible proportion of them requiring regular hemo dialysis and occasionally renal transplantation.

Keywords: bilateral, Wilms' tumor, synchronous, nephron-sparing surgery, Children, Egypt, CCHE, 57357

Received: 18 May 2025; Accepted: 10 Oct 2025.

Copyright: © 2025 Asfour, Khaled Zekri, Hussein, ElKinaai, Sobhy, Helmi, Nasr, Refaat, Gamal, Younes, El-Ayadi and Khalil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hosam Y. Asfour, hosam.yusri@57357.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.